GSK eyes life after a patent cliff
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline is shifting "from being a blockbuster-dependent" company that relies on a single patented drug for a bulk of its revenue to a "blockbuster-ready" firm with a well-diversified portfolio that provides protection if the next big drug comes too late to offset generic competition for the current top-seller, CEO Andrew Witty says. At Cowen & Co.'s Health Care Conference March 17 in Boston, Witty said GSK is seeking diversity rather than the next blockbuster drug to "diminish the possibility of simply going back to another patent cliff," like the one it fell off last year when it lost exclusivity for several prescription drugs. GSK will invest in multiple small prescription drugs and seeks bolt-on acquisitions of vaccines and brands in "the consumer emerging market" to reduce the impact of any one patent expiry, Witty said (1"The Tan Sheet" Feb. 9, 2009, p. 9)
You may also be interested in...
GSK Invests In Consumer Unit To Overcome Generic Threat, Low Alli Sales
GlaxoSmithKline expects to overcome increasing generic competition by growing its consumer health business and investing in emerging markets, rather than by pursuing a mega-merger like Pfizer-Wyeth
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.